AstraZeneca: Diabetes Mellitus, Type 2 trials

The registry lists 345 Diabetes Mellitus, Type 2 studies with AstraZeneca as lead sponsor. 13 are open to participants now and 149 have results posted.

Phase 1 89Phase 2 47Phase 3 122Phase 4 28No phase 65(a study in two phases counts in both)

Studies

Page 2 of 4. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Multiple Doses of Saxagliptin (BMS-477118)CompletedNCT00950599Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes MellitusCompletedNCT00935532Phase 3Results posted
• Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic ControlCompletedNCT00918879Phase 3Results posted
• Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mgCompletedNCT00918138Phase 3Results posted
• A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian SubjectsCompletedNCT00917267Phase 3Results posted
• Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)CompletedNCT00899470Phase 1Results posted
• Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)CompletedNCT00897390Phase 1Results posted
• A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly SuspensionCompletedNCT00894322Phase 1/2Results posted
• Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes MellitusCompletedNCT00885378Phase 3Results posted
• A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)CompletedNCT00877890Phase 3Results posted
• A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus MetforminCompletedNCT00870194Phase 4Results posted
• Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 DiabetesCompletedNCT00859898Phase 3Results posted
• Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 DiabetesCompletedNCT00856908Phase 2Results posted
• Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 DiabetesCompletedNCT00855166Phase 3Results posted
• Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 DiabetesCompletedNCT00831779Phase 2Results posted
• Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With MetforminCompletedNCT00817778Phase 2Results posted
• Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes MellitusCompletedNCT00765817Phase 3Results posted
• Safety and Efficacy of Saxagliptin Plus Insulin With or Without MetforminCompletedNCT00757588Phase 3Results posted
• Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With MetforminCompletedNCT00753896Phase 3Results posted
• A Diabetes Study to Treat A Population Previously Not at TargetCompletedNCT00747149Phase 4Results posted
• Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 DiabetesCompletedNCT00736879Phase 3Results posted
• Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a ThiazolidinedioneCompletedNCT00729326Phase 4Results posted
• Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic ControlCompletedNCT00698932Phase 3Results posted
• Add-on to Thiazolidinedione (TZD) FailuresCompletedNCT00683878Phase 3Results posted
• Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR AloneCompletedNCT00683657Phase 3Results posted
• Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes PatientsCompletedNCT00680745Phase 3Results posted
• Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)CompletedNCT00676338Phase 3Results posted
• Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on InsulinCompletedNCT00673231Phase 3Results posted
• 18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)CompletedNCT00666458Phase 3Results posted
• Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal ImpairmentCompletedNCT00663260Phase 2/3Results posted
• Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 DiabetesCompletedNCT00661362Phase 3Results posted
• Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes PatientsCompletedNCT00660907Phase 3Results posted
• Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 DiabetesCompletedNCT00658021Phase 3Results posted
• An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release TabletsCompletedNCT00643851Phase 3Results posted
• Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)CompletedNCT00641056Phase 3Results posted
• A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)CompletedNCT00637273Phase 3Results posted
• CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE TherapyCompletedNCT00635492Results posted
• Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal ImpairmentCompletedNCT00614939Phase 3Results posted
• Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and MetforminCompletedNCT00603239Phase 3Results posted
• Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)CompletedNCT00577824Phase 3Results posted
• 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension PeriodCompletedNCT00575588Phase 3Results posted
• A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin AloneCompletedNCT00528879Phase 3Results posted
• A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and ExerciseCompletedNCT00528372Phase 3Results posted
• A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 DiabetesCompletedNCT00516074Phase 3Results posted
• An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 DiabetesCompletedNCT00516048Phase 3Results posted
• A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 DiabetesCompletedNCT00467649Phase 4Results posted
• Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 DiabetesCompletedNCT00434954Phase 3Results posted
• Effect on Weight Loss of Exenatide Versus PlaceboCompletedNCT00375492Phase 3Results posted
• A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and ExerciseCompletedNCT00374907Phase 3Results posted
• A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes PatientsCompletedNCT00360334Phase 3Results posted
• Exenatide Versus Glimepiride in Patients With Type 2 DiabetesCompletedNCT00359762Phase 3Results posted
• A Pilot Study of BMS-512148 in Subjects With Type 2 DiabetesCompletedNCT00357370Phase 2/3Results posted
• Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)CompletedNCT00308139Phase 3Results posted
• A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy AloneCompletedNCT00295633Phase 3Results posted
• DIabetic Retinopathy Candesartan TrialsCompletedNCT00252694Phase 3Results posted
• An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 DiabetesCompletedNCT00229658Results posted
• An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes MellitusCompletedNCT00135330Phase 3Results posted
• Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin AloneCompletedNCT00121667Phase 3Results posted
• Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and ExerciseCompletedNCT00121641Phase 3Results posted
• Effects of Exenatide and Insulin Glargine in Subjects With Type 2 DiabetesCompletedNCT00097500Phase 3Results posted
• Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and MetforminCompletedNCT00082407Phase 3Results posted
• Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and MetforminCompletedNCT00082381Phase 3Results posted
• A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy ParticipantsActive, not recruitingNCT07534592Phase 1
• A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 YearsCompletedNCT07455825Phase 1
• A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy ParticipantsCompletedNCT07444424Phase 1
• A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes MellitusSuspendedNCT07433062Phase 1
• A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral FormulationsCompletedNCT06996886Phase 1
• A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy ParticipantsCompletedNCT06948747Phase 1
• A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female ParticipantsCompletedNCT06942936Phase 1
• A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With ObesityCompletedNCT06942923Phase 1
• Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor AgonistCompletedNCT06851858Phase 2
• A Study to Investigate Multiple Ascending Doses of AZD5004 in Healthy Japanese Participants and Participants With Type 2 Diabetes MellitusCompletedNCT06703658Phase 1
• Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.CompletedNCT06579105Phase 2
• A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy ParticipantsCompletedNCT06555822Phase 1
• Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DMCompletedNCT06327815Phase 4
• A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and OverweightActive, not recruitingNCT06151964Phase 1/2
• Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)CompletedNCT06099067
• A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186TerminatedNCT05694741Phase 1
• Chinese Multiple Dose Escalation (MDE) High Dose StudyCompletedNCT05437848Phase 1
• A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy SubjectsCompletedNCT05294458Phase 1
• Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single ComponentsCompletedNCT05266404Phase 1
• QTERN (SAXAGLIPTIN/DAPAGLIFLOZIN FDC) Regulatory Post-Marketing SurveillanceCompletedNCT05160974
• Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes MelitusCompletedNCT04208620Phase 1
• A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese SubjectsCompletedNCT04142424Phase 1
• A Study Investigating the Pharmacokinetics of a Single Dose Administration of CotadutideCompletedNCT04091373Phase 1
• An Observational Study to Assess the Prevalence of Heart Failure in Type 2 Diabetes PatientsCompletedNCT04072523
• Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes MellitusWithdrawnNCT04001231Phase 1
• Characteristics of Patients With Type 2 Diabetes Mellitus (CVD-RNDR)CompletedNCT03694470
• DAPA - Egypt StudyCompletedNCT03624803
• Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/SaxagliptinTerminatedNCT03608358Phase 3
• Dapagliflozin in Type 2 Diabetes Patients, a Retrospective Cohort Study From TurkeyCompletedNCT03407196
• Indian Phenotype RegistryCompletedNCT03363594
• Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382CompletedNCT03347968Phase 1
• A Phase IV Study in Drug-Naive Patients With T2DM in ChinaTerminatedNCT03344341Phase 4
• A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382CompletedNCT03341013Phase 1
• Type 2 Diabetes Mellitus Patients' Characteristics and Management by General Practitioners and EndocrinologistsCompletedNCT03209089
• A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.CompletedNCT03169959Phase 1
• Multi-center, Single Arm, Observational Study to Evaluate the Safety of Dapagliflozin in Type 2 Diabetes Mellitus Patients in ChinaCompletedNCT03156985
• Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy SubjectsCompletedNCT03138356Phase 1
• A 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With T2DMCompletedNCT03090464